The Latest Breaking News from Pfizer Inc

Pfizer (PFE) is spending its COVID-19 cash flows on meaningful growth avenues. However, given a recent downgrade, should value investors still be excited about this stock? Let’s look at the trends of its financial metrics to get an idea….

Goldman Sachs research suggests the global pharmaceutical sector has approximately $700 billion available for M&A and investments

Moderna Inc. will push toward producing messenger RNA vaccines for China, seeking a foothold in the world’s second-largest pharmaceutical market even as geopolitical tensions rise.

The pharma sector is poised to witness significant growth due to the widespread adoption of generic medicines and emerging technologies. Therefore, fundamentally strong pharma stocks Pfizer (PFE), Sanofi (SNY), and Spero Therapeutics (SPRO) might be solid buys. Read on.

Pfizer Inc cautions about potential supply shortages for pediatric Bicillin L-A, an antibiotic for syphilis treatment.

Despite a slowdown of Covid-19 vaccine sales in the last reported quarter, biopharmaceutical giant Pfizer (PFE) is positioned to deliver robust growth this year and beyond, thanks to the strength of its in-line products and expected near-term launches and revenue distribution from the recent acquisition. So, let’s find out if…

After more than three years, the global COVID-19 emergency is officially over. Yet it’s still killing at least one person every four minutes and questions on how to deal with the virus remain unanswered, putting vulnerable people and undervaccinated countries at risk.

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out….

The biotech industry is growing thanks to breakthrough advancements and government initiatives. Furthermore, during market downturns, the biotech sector is more defensive than others. So, fundamentally sound biotech stocks Pfizer (PFE) and AstraZeneca (AZN) could be worth buying. Read on.

Recent banking turmoil and rising interest rates have weighed heavily on investors’ sentiment lately. However, weak economic data signaling slowing growth could result in relatively easy monetary policies in the second half of 2023. Given the macroeconomic backdrop, investors could consider adding fundamentally sound low P/E stocks Pfizer (PFE), Chevron…

Popular brokerage company Robinhood (HOOD) attracts millennials and Generation Z traders by offering zero-commission financial services. While not all stocks traded on this platform possess fundamental strength, investors could consider buying fundamentally sound Robinhood stocks Visa (V) and Pfizer (PFE) and holding them for the long term. Keep reading….